The estimated Net Worth of Jonathan Finn is at least $38 Mille dollars as of 10 April 2024. Jonathan Finn owns over 25,000 units of Atossa Therapeutics Inc stock worth over $38,000 and over the last few years Jonathan sold ATOS stock worth over $0.
Sign up
Jonathan Finn ATOS stock SEC Form 4 insiders trading
Jonathan has made over 1 trades of the Atossa Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Jonathan bought 25,000 units of ATOS stock worth $44,250 on 10 April 2024.
The largest trade Jonathan's ever made was buying 25,000 units of Atossa Therapeutics Inc stock on 10 April 2024 worth over $44,250. On average, Jonathan trades about 8,333 units every 0 days since 2023. As of 10 April 2024 Jonathan still owns at least 25,000 units of Atossa Therapeutics Inc stock.
You can see the complete history of Jonathan Finn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jonathan Finn's mailing address?
Jonathan's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC.,, 107 SPRING STREET, SEATTLE, WA, 98104.
Insiders trading at Atossa Therapeutics Inc
Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over $114,740 worth of Atossa Therapeutics Inc stock and bought 274,300 units worth $204,285 . The most active insiders traders include Gregory L Weaver, Steven C Quay e Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of $38,260. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth $44,250.
What does Atossa Therapeutics Inc do?
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
What does Atossa Therapeutics Inc's logo look like?
Complete history of Jonathan Finn stock trades at Atossa Therapeutics Inc
Atossa Therapeutics Inc executives and stock owners
Atossa Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Steven Quay,
Chairman of the Board, President, Chief Executive Officer -
Kyle Guse,
Chief Financial Officer, General Counsel, Secretary -
Dr. Steven C. Quay,
Chairman, CEO & Pres -
Kyle Guse CPA, Esq., CPA,
CFO, Gen. Counsel & Sec. -
Shu-Chih Chen,
Director -
Gregory Weaver,
Independent Director -
Scott Gordon,
IR Contact Officer -
Richard Steinhart,
Independent Director -
H. Lawrence Remmel,
Independent Director -
Stephen Galli,
Independent Director -
Janet Rose Rea MSPH, RAC,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Delly Behen P.H.R.,
VP of Admin. & HR -
Heather Rees,
VP of Fin. & Accounting -
Janet Rose Rea,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Scott Youmans,
Chief Operating Officer -
Heather Rees,
SVP, Finance and Accounting -
Jonathan Finn,
-
Tessa Cigler,
-
Christopher S. Destro,
Sr. VP, Sales and Marketing -
John Barnhart,
Director -
John E Sawyer,
See Remarks -
Peter J. Carbonaro,
Sr. Vice President, Operations -
Ben R Chen,
Sr. VP of Glob. Reg. Affairs -
Alexander D Cross,
Director